Duopharma Biotech Bhd

Duopharma Biotech Bhd FCF Yield

The Free Cash Flow Yield of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 3, 2026 is 3.47 %. In the previous year, Free Cash Flow Yield was 0.65 % — a change of 434.95% (higher).

FCF Yield

3.47 %

YoY

434.95%

Last updated:

Free Cash Flow Yield of Duopharma Biotech Bhd is 2024 3.47 % . Free Cash Flow Yield of Duopharma Biotech Bhd was 2023 0.65 % . It decreases by 434.95% higher compared to the previous year.

The Duopharma Biotech Bhd FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2017
-1.30 MYR
Jan 1, 2018
-1.43 MYR
Jan 1, 2019
0.43 MYR
Jan 1, 2020
0.40 MYR
Jan 1, 2021
-5.04 MYR
Jan 1, 2022
-0.05 MYR
Jan 1, 2023
0.65 MYR
Jan 1, 2024
3.47 MYR
The Duopharma Biotech Bhd FCF Yield history
YEARFCF YieldYoY
3.47 %+434.95%
0.65 %-1,322.75%
-0.05 %-98.95%
-5.04 %-1,352.65%
0.40 %-5.54%
0.43 %-129.72%
-1.43 %+10.14%
-1.30 %+1,185.71%
-0.10 %-98.44%
-6.48 %-491.97%
1.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

Free Cash Flow Yield of Duopharma Biotech Bhd is 3.47 % in 2024.

Free Cash Flow Yield of Duopharma Biotech Bhd changed from 0.65 % to 3.47 %, representing a 434.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Duopharma Biotech Bhd with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd